Tag: Venous thromboembolism
Rivaroxaban improves clinical outcomes in discharged COVID-19 patients
COVID-19: Thromboembolic risk reduction with therapeutic heparin dosing
Haemostatic abnormalities are associated with mortality in COVID-19
PCSK9 inhibition as primary prevention for VTE: Is it LDL or Lp(a)?
PAD: Rivaroxaban reduces VTE risk after revascularisation
Similar bleeding rates in patients with VTE and AF treated with DOACs
Residual pulmonary obstruction may predict risk of VTE recurrence
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
Lower embryopathy risk with DOAC versus VKA during pregnancy
Higher thrombotic risk in NSCLC patient with ALK rearrangement
